Introduction {#s1}
============

The demographic transition in India has resulted in the label of an ageing nation [@pone.0088045-Ingle1]. The Government of India\'s 'National Policy on Older Persons' defines 'elderly' as a person who is of age 60 years or above [@pone.0088045-Situational1]. In 2001, the proportion of elderly in India was about 7.4% of the overall population which increased to 8.3% in 2011 [@pone.0088045-Situational1], [@pone.0088045-Rath1]. A decline in immunity and age related physiological changes leads to an increased burden of communicable and non-communicable diseases in the elderly [@pone.0088045-Ingle1].

India is the highest tuberculosis (TB) burden country accounting for a quarter (26%) of the global incidence [@pone.0088045-WHOGlobal1]. About 90% of TB in the elderly is due to endogenous reactivation [@pone.0088045-Stead1]. Co-morbidities, inter-current illness, malnutrition, excess alcohol use, underlying malignancy and the use of immunosuppressant drugs can impair the cell-mediated immunity in the elderly causing progression to TB disease [@pone.0088045-Schaaf1]. New smear positive TB case notification in India in those aged 55 yrs and above showed an increase from 31133 to 132938 between the years 2000 to 2012 [@pone.0088045-WHOGlobal1]. This increase in TB case notifications may partly be due to the increase in the elderly population and is expected to rise further since the proportion of elderly (≥60 yrs) in India projected for 2026 is about 12.17% of the overall population [@pone.0088045-Ingle1]. A study from South India has documented that older TB patients (≥60 yrs) accounted for 14% of all TB patients [@pone.0088045-Ananthakrishnan1]. There is limited data on the profile of elderly TB patients and their treatment outcomes in India [@pone.0088045-Ananthakrishnan1]--[@pone.0088045-Pardeshi1]. The objective of this study was to compare the clinical profile, presentation and response to anti-TB treatment among the elderly (≥60 yrs) and younger (15--59 yrs) TB patients treated under the Revised National TB Control programme (RNTCP).

Methodology {#s2}
===========

Study area and participants {#s2a}
---------------------------

This was a retrospective analysis of a cohort of TB patients registered for anti-TB treatment from May 1999 to December 2004 in one Tuberculosis Unit (TU) of Tiruvallur District, Tamil Nadu State, South India \[Under the RNTCP, a TU is a sub-district supervisory unit which covers on average a population of 500,000\]. This TU has 17 government health care facilities including seven designated microscopy centres.

National Institute for Research in TB (NIRT) (formerly Tuberculosis Research Centre) was monitoring the TB programme implemented by the Government of Tamil Nadu in one TU of Tiruvallur district, since May 1999. TB cases were diagnosed by testing symptomatic patients at health facilities through the examination of three sputum smears for acid-fast bacilli (passive screening). In addition, the centre was conducting epidemiological surveys from 1999 to measure the prevalence of TB (active screening) in this TU. Approval of the Ethics Committee of NIRT was obtained and written informed consent was obtained from all the patients (aged≥18 yrs) and from guardian/care-givers for those aged 15 to less than 18 yrs.

All patients diagnosed with TB were given directly observed treatment in accordance with the RNTCP guidelines with first line anti-TB drugs which include isoniazid (H), rifampicin (R), pyrazinamide (Z), ethambutol (E) and streptomycin (S) [@pone.0088045-Central1]. Newly diagnosed TB patients received Category I (2H~3~R~3~Z~3~E~3~/4H~3~R~3~) or Category III (2H~3~R~3~Z~3~/4H~3~R~3~) anti-TB regimens, while previously treated TB patients received Category II regimen (2H~3~R~3~Z~3~E~3~S~3~/1H~3~R~3~Z~3~E~3~/5H~3~R~3~E~3~) [@pone.0088045-Central1]. The treatment was extended for one month if the smears were positive at the end of the intensive phase (IP) in Categories I and II. Every dose of treatment in IP, and at least the first of the three doses during the continuation phase were given under supervision. Details of patients who began treatment were noted in the register, and they were monitored in accordance with the RNTCP guidelines [@pone.0088045-Central1].

Data collection {#s2b}
---------------

The information about type of disease (pulmonary or extra-pulmonary), category of disease, grade of smear and baseline weight (in kg) was obtained from the treatment cards. Two sputum samples were collected from each patient for smear and culture on Lowenstein Jensen (L-J) medium, within a week of treatment initiation. The specimens that yielded growth were tested for drug susceptibility. Resistance to H and R was determined by the absolute concentration method minimum inhibitory concentration (MIC) and to S by resistance ratio (RR) method [@pone.0088045-Allen1], [@pone.0088045-Canetti1]. MICs of ≥5 mg/l and of ≥128 mg/l were defined as resistance to H and R, respectively. A RR of ≥8 was considered as resistance to S [@pone.0088045-Tuberculosis1].

Within 8 weeks from the start of treatment, trained medical social workers (MSW) interviewed patients using a structured questionnaire to obtain information about education, co-morbid conditions, personal habits, chest symptoms, care-seeking behaviour and drug related problems. MSW\'s made three attempts to contact each patient for the interview.

Upon completion of treatment, each patient\'s treatment card was again reviewed to collect information about follow-up sputum smear results and treatment outcomes.

Case definitions {#s2c}
----------------

Patients aged ≥60 yrs were defined as elderly and those aged 15--59 years as younger. RNTCP definitions were used to classify the type of TB, category and treatment outcomes [@pone.0088045-Central1].

Patients who could read and write were considered literate; those who said they habitually consumed alcohol or smoked as alcohol users or smokers respectively, patients on treatment with hypoglycaemics were considered diabetics.

Multidrug resistance (MDR-TB) was defined as resistance to both H and R, with or without resistance to other drugs.

Study outcome {#s2d}
-------------

The younger and elderly group were compared by gender, body weight in Kg, literacy rate, employment status, diabetes, asthma, smoking, alcohol use, respiratory symptoms and its duration, type of TB, sputum smear status, side effects and drug susceptibility profile. TB treatment outcomes were compared as; those cured, treatment completed, failed, loss to follow-up (referred to as 'default' in RNTCP nomenclature), died and transferred out.

Data entry and analysis {#s2e}
-----------------------

Data were double-verified, entered and analysed using SPSS version 14.0 (Statistical Package for the Social Sciences Inc, Chicago, IL, USA). Variables were expressed as proportions. Statistical differences between the elderly and younger groups were determined with chi-square test and Yates correction, except when expected values of less than 5 required the use of the Fisher exact test. Significance was determined at 5%. Crude odds ratios (OR) and 95% confidence intervals (CI) were determined using "younger" as the reference group.

Results {#s3}
=======

Patient characteristics {#s3a}
-----------------------

From May 1999 through December 2004, 5368 TB patients were registered for treatment. Patients aged \<15 yrs (n = 65) and those on non- supervised TB treatment (n = 95) were excluded. Among the remaining 5208 patients included in the analysis, there were 865 elderly (60--90 yrs) and 4343 younger (15--59 yrs) TB patients.

The median age in the elderly group was 65 years (IQR: 60--68) and younger group was 39 years (IQR: 28--49). The baseline characteristics of elderly and younger patients are shown in [Table 1](#pone-0088045-t001){ref-type="table"}. The socio-demographic profile of elderly showed a male preponderance (84% vs. 71%; p\<0.001), higher illiteracy (63% vs. 45%; p\<0.001) and unemployment (58% vs. 35%; p\<0.001) ([Table 1](#pone-0088045-t001){ref-type="table"}). The mean body weight was similar in both the groups; elderly 41 kg (range 24--77 kg) and younger 42 kg (range 21--94 kg).The proportion of patients who smoked was higher in the elderly (46% vs. 37%; p\<0.001) while the consumption of alcohol was not different (29% and 30%). Prevalence of reported diabetes mellitus did not differ in both the groups (6% vs. 5%).

10.1371/journal.pone.0088045.t001

###### Baseline characteristics of TB patients in the elderly and younger group.

![](pone.0088045.t001){#pone-0088045-t001-1}

  Characteristics                                         Elderly n = 865   Younger n = 4343   OR (95% CI)[\$](#nt103){ref-type="table-fn"}   P value                      
  ------------------------------------------------------ ----------------- ------------------ ---------------------------------------------- --------- ------------------- ---------
  **Male**                                                      723               *84*                             3083                        *71*     2.08 (1.72--2.52)   \<0.001
  **Body wt** [\*](#nt101){ref-type="table-fn"} ≤40 Kg          385               *48*                             1838                        *45*      1.1(0.96--1.31)     0.13
  **Illiterate** [\*\*](#nt102){ref-type="table-fn"}            541               *63*                             1941                        *45*     2.06 (1.78--2.39)   \<0.001
  **Un-employed**                                               498               *58*                             1506                        *35*     2.56 (2.20--2.97)   \<0.001
  **Co-morbidity**                                                                                                                                                         
  **Diabetic** [\*\*](#nt102){ref-type="table-fn"}              52                *6*                              206                          *5*     1.28 (0.94--1.76)    0.118
  **Habits**                                                                                                                                                               
  **Smoker** [\*\*](#nt102){ref-type="table-fn"}                396               *46*                             1623                        *37*     1.41 (1.22--1.64)   \<0.001
  **Alcohol use** [\*\*](#nt102){ref-type="table-fn"}           250               *29*                             1315                        *30*     0.93 (0.79--1.09)    0.415

\*Details not available for 55 patients in the elderly group and 222 in the younger.

\*\*Details not available for 2 patients in the younger group.

Odds ratio (95% CI) calculated with younger group as reference using chi-square test.

TB symptoms and diagnosis ([Table 2](#pone-0088045-t002){ref-type="table"}) {#s3b}
---------------------------------------------------------------------------

Pulmonary TB disease (96% vs. 91%; p\<0.001) and eligibility for Category III ie.smear negative and non-severe extra-pulmonary TB (41% vs. 33%; p\<0.001) were higher among the elderly ([Table 2](#pone-0088045-t002){ref-type="table"})

10.1371/journal.pone.0088045.t002

###### TB symptoms, diagnosis and treatment in the elderly and younger group.

![](pone.0088045.t002){#pone-0088045-t002-2}

  Characteristics                                                                                                                               Elderly n = 865   Younger n = 4343   OR (95% CI)[\$](#nt106){ref-type="table-fn"}   P value                      
  ------------------------------------------------------------------------------------------- ------------------------------------------------ ----------------- ------------------ ---------------------------------------------- --------- ------------------- ---------
  **Type of disease**                                                                                            Pulmonary                            834                96                              3943                         91      2.73 (1.88--3.96)   \<0.001
  **Case detection**                                                                                          Survey (Active)                         168                19                              481                          11      1.83 (1.49--2.23)   \<0.001
  **Anti-TB treatment**                                                                                                                                                                                                                                          
  New patients                                                                                                   Category I                           397                46                              2205                         51      0.82 (0.71--0.95)    0.01
                                                                                                                Category III                          356                41                              1447                         33      1.39 (1.20--1.63)   \<0.001
  Previously treated                                                                                            Category II                           112                13                              691                          16      0.79 (0.63--0.98)    0.03
  **Pulmonary TB**                                                                                                                                **n = 834**                                        **n = 3943**                                                
  **Symptoms (Irrespective of duration)**                                                                                                                                                                                                                        
                                                                                                   Cough[\*](#nt104){ref-type="table-fn"}             700                84                              3290                         83       1.04 (0.8--1.3)     0.758
                                                                                               Breathlessness[@](#nt105){ref-type="table-fn"}         336                40                              1421                         36       1.4 (1.2--1.6)      0.021
                                                                                                Chest pain[\*](#nt104){ref-type="table-fn"}           520                62                              2569                         65       0.9 (0.8--1.04)     0.130
                                                                                                Hemoptysis[\*](#nt104){ref-type="table-fn"}           198                24                              1115                         28       0.8 (0.7--0.9)      0.008
  **First action for relief from respiratory complaints** [\*](#nt104){ref-type="table-fn"}                         Govt                              419                50                              1829                         46       1.2 (1.0--1.4)      0.043
  Private                                                                                                                                             289                35                              1600                         41       0.8 (0.7--0.9)      0.002
  Home/Pharmacy                                                                                                                                       120                14                              503                          13       1.1 (0.9--1.4)      0.204
  Alternate Medicine                                                                                                                                   6                 1                                11                          \<1      2.6 (0.8--7.7)      0.052
  **Anti-TB treatment**                                                                                                                                                                                                                                          
  New patients                                                                                                   Category I                           389                47                              2117                         54       0.7 (0.6--0.9)     \<0.001
                                                                                                                Category III                          333                40                              1143                         29       1.6 (1.4--1.9)     \<0.001
  Previously treated                                                                                            Category II                           112                13                              683                          17       0.7 (0.6--0.9)      0.006
  **Sputum smear**                                                                                                Negative                            385                46                              1408                         36       1.54 (1.3--1.8)    \<0.001

\*Details not available for 2 patients in the younger group.

Details not available for 223 patients in the elderly and 1114 patients in the younger group.

Odds ratio (95% CI) calculated with younger group as reference using chi-square test.

Of the 834 elderly and 3943 younger pulmonary TB patients, 109 (13%) and 488 (12%) were asymptomatic respectively (OR, 1.06; 95%CI, 0.85--1.34); p = 0.582. Among the symptomatics, a higher proportion of elderly TB patients (40% vs. 36%; p = 0.021) reported breathlessness, while cough was similar between the two groups (84% vs. 83%). ([Table 2](#pone-0088045-t002){ref-type="table"}) The RNTCP definition of a TB suspect during the period of this study was cough of more than 3 weeks duration. Among the 700 elderly and 3290 younger pulmonary TB patients who reported cough, duration of ≥21 days was reported by 627 (89%) of elderly and 2922 (89%) younger patients; p = 0.56. Among the 336 elderly and 1421 younger patients with breathlessness, duration of ≥21 days duration was reported by 296 (88%) of elderly and 1195 (84%) younger patients; p = 0.07. There was no difference in the duration of symptoms (≥21 days) prior to diagnosis, between the elderly and younger TB patients

Elderly patients were less likely to contact a private provider as their first action for relief from respiratory complaints (35% vs. 41%; p = 0.002). ([Table 2](#pone-0088045-t002){ref-type="table"}) The median duration between onset of symptoms and the first action was 2 weeks (IQR: 1--4) and did not differ between the elderly and the younger group. Initial sputum smear negativity (46% vs. 36%; p\<0.001) was higher in the elderly with pulmonary TB.

All the 649 patients identified by active case finding during a prevalence survey had pulmonary TB. The proportion with asymptomatic disease was higher among those identified through active case finding (15% vs. 12%; p = 0.021) compared to passive case finding. Breathlessness (53% vs. 35%; p\<0.001) and hemoptysis (28% vs. 23%; p\<0.01) were higher among those identified by passive case finding while proportion of those with cough was similar (83% vs. 85%; p = 0.43) in active and passive case finding. The proportion of patients with symptoms of ≥21 days duration was higher in the group identified by active compared to passive case finding; cough (92% vs. 88%; p\<0.01), breathlessness (90% vs. 84%; p\<0.001).Smear negativity rate (43% vs. 37%; p\<0.001) was higher among those identified by active case finding compared to passive case finding.

Active case finding identified a higher proportion of elderly with TB (19% vs. 11%; p\<0.001). ([Table 2](#pone-0088045-t002){ref-type="table"}) There were no significant differences between the elderly and younger with respect to symptoms and their duration in patients detected by active case finding. The sputum smear negativity rate was similar between the two groups in active case finding, however sputum smear negativity rate was higher in elderly in passive case finding (46% vs. 35%; p\<0.001).

Drug resistance, smear conversion and treatment outcomes in newly diagnosed TB patients {#s3c}
---------------------------------------------------------------------------------------

### Category I {#s3c1}

There were 397 elderly and 2205 younger patients who were treated with the Category I regimen. Overall elderly patients had less favorable outcome i.e cured/treatment completed (71% vs. 80%; p\<0.001) with more defaulters (14% vs. 11%; p = 0.09) and deaths (10% vs. 4%; p\<0.001).([Table 3](#pone-0088045-t003){ref-type="table"}) Data on drug-related problems, due to the bulk of drugs or side effects was available for 289 elderly and 1648 younger TB patients. Elderly 183 (63%) reported more problems compared to the younger 897 (54%); (OR, 1.44; 95%CI, 1.12--1.87); p = 0.005.

10.1371/journal.pone.0088045.t003

###### Drug susceptibility profile, Smear conversion and TB Treatment outcomes in newly diagnosed TB patients in the elderly and younger group.

![](pone.0088045.t003){#pone-0088045-t003-3}

                                                                           Elderly                    Younger           OR (95% CI)[\$](#nt107){ref-type="table-fn"}   P value
  --------------------------------------------------------------------- ------------- -------------- --------- ------- ---------------------------------------------- ---------
  **Category I**                                                         **n = 397**   **n = 2205**                                                                   
  **Overall treatment outcome**                                             **n**         **%**        **n**    **%**                                                 
  Cured/Treatment Completed                                                  283           *71*        1770     *80*                 0.61 (0.48--0.78)                 \<0.001
  Failure                                                                    17            *4*          97       *4*                 1.97 (0.54--1.66)                  0.92
  Loss to follow-up                                                          56            *14*         247     *11*                 1.30 (0.90--1.80)                  0.09
  Death                                                                      38            *10*         86       *4*                 2.60 (1.70--3.90)                 \<0.001
  Transferred                                                                 3            *1*           5      *\<1*                3.75 (0.89--15.79)                 0.07
  **Smear positive PTB**                                                 **n = 352**   **n = 1933**                                                                   
  **Smear conversion at the end of Intensive phase**                        **n**         **%**        **n**    **%**                                                 
  Yes                                                                        272            77         1651      85                  0.58 (0.44--0.77)                 \<0.001
  **Culture result available**                                           **n = 336**   **n = 1856**                                                                   
  Positive                                                                   294           *88*        1602     *86*                 1.20 (0.80--1.60)                  0.55
  **Drug susceptibility available**                                      **n = 293**   **n = 1597**                                                                   
  Sensitive                                                                  256           *87*        1349     *84*                 1.27 (0.87--1.90)                  0.20
  Any resistance                                                                                                                                                      
  H                                                                          21            *7*          169     *11*                 0.65 (0.40--1.10)                  0.08
  SM                                                                         21            *7*          141      *9*                 0.79 (0.47--1.29)                  0.35
  R                                                                           4            *1*          30       *2*                 0.72 (0.18--2.07)                  0.54
  HR                                                                          3            *1*          25       *2*                 0.65 (0.12--2.15)                  0.48
  **Treatment outcome of smear positive PTB treated with Category I**                                                                                                 
  Cured/Treatment completed                                                  248           *70*        1546     *80*                 0.60 (0.46--0.78)                 \<0.001
  Failure                                                                    16            *5*          96       *5*                  0.91(0.49--1.58)                  0.74
  Loss to follow-up                                                          54            *15*         219     *11*                  1.40 (1.0--1.97)                  0.03
  Death                                                                      31            *9*          68       *4*                  2.60 (1.6--4.20)                 \<0.001
  Transferred                                                                 3            *1*           4      *\<1*                4.67 (1.04--21.01)                 0.04
  **Category III**                                                       **n = 356**   **n = 1447**                                                                   
  **Treatment outcome**                                                     **n**         **%**        **n**    **%**                                                 
  Treatment Completed                                                        275           *77*        1238     *85*                 0.57 (0.43--0.77)                 \<0.001
  Failure                                                                     6            *2*          19       *1*                 1.30 (0.42--3.39)                  0.59
  Loss to follow-up                                                          56            *16*         142     *10*                 1.70 (1.20--2.40)                  0.001
  Death                                                                      19            *5*          45       *3*                 1.81 (0.96--3.11)                  0.04
  Transferred                                                                 0            *0*           3      *\<1*                        NA                         **-**

Odds ratio (95% CI) calculated with younger group as reference using chi-square test.

Among smear positive patients (352 elderly and 1933 younger), lower smear conversion rate at the end of IP (77% vs. 85%; p\<0.001) and higher loss to follow-up (15% vs. 11%; p = 0.03) and death rates (9% vs. 4%; p\<0.001) were observed in the elderly. ([Table 3](#pone-0088045-t003){ref-type="table"})

Drug susceptibility results were available for the 293 elderly and 1597 younger patients. Similar proportions of patients had *Mycobacterium tuberculosis (M.tb)* susceptible to all first line anti-TB drugs (elderly 87% vs. younger 84%) with no difference in MDR-TB rates. ([Table 3](#pone-0088045-t003){ref-type="table"})

### Category III {#s3c2}

There were 356 elderly and 1447 younger patients who were treated with the Category III regimen. Elderly patients were less likely to complete treatment (77% vs. 85%; p\<0,001) and more likely to be lost to follow-up (16% vs. 10%; p = 0.001). ([Table 3](#pone-0088045-t003){ref-type="table"})

Among 252 elderly and 1014 younger TB patients with data available, elderly 95 (38%) reported less drug related problems compared to the younger group 532 (52%); (OR, 0.55; 95%CI, 0.41--0.73); p\<0.0001.

Drug resistance, smear conversion and TB Treatment outcomes in previously treated TB patients {#s3d}
---------------------------------------------------------------------------------------------

There were 112 elderly and 691 younger patients who were treated with the Category II regimen. Treatment outcomes did not differ between the groups. ([Table 4](#pone-0088045-t004){ref-type="table"}) Drug related problems were similar; (elderly 38 (48%) vs. younger 261 (55%); (OR, 0.73; 95%CI, 0.46--1.18); p = 0.20 among 80 elderly and 473 younger patients for whom data was available.

10.1371/journal.pone.0088045.t004

###### Drug susceptibility profile, Smear conversion and TB Treatment outcomes in previously treated TB patients in the elderly and younger group.

![](pone.0088045.t004){#pone-0088045-t004-4}

                                                                            Elderly                   Younger           OR (95% CI)[\$](#nt108){ref-type="table-fn"}   P value
  ---------------------------------------------------------------------- ------------- ------------- --------- ------- ---------------------------------------------- ---------
  **Category II**                                                         **n = 112**   **n = 691**                                                                   
  **Overall treatment outcome**                                              **n**         **%**       **n**    **%**                                                 
  Cured/Treatment Completed                                                   54            48          316      46                  1.10 (0.72--1.68)                  0.62
  Failure                                                                      4             4          57        8                  0.41 (0.14--1.18)                  0.10
  Loss to follow-up                                                           40            36          264      38                  0.90 (0.60--1.40)                  0.61
  Death                                                                       11            10          47        7                  1.50 (0.70--3.00)                  0.25
  Transferred                                                                  3             3           7        1                  2.51 (0.63--9.99)                  0.19
  **Smear positive PTB**                                                  **n = 97**    **n = 602**                                                                   
  **Smear conversion at the end of Intensive phase**                         **n**         **%**       **n**    **%**                                                 
  Yes                                                                         65            67          362      60                  1.35 (0.86--2.12)                  0.20
  **Culture result available**                                            **n = 92**    **n = 552**                                                                   
  Positive                                                                    67            73          453      82                  0.60 (0.34--1.02)                  0.04
  **Drug susceptibility available**                                       **n = 66**    **n = 452**                                                                   
  Sensitive                                                                   42            64          263      58                  1.26 (0.72--2.25)                  0.40
  Any resistance                                                                                                                                                      
  H                                                                           20            30          167      37                  0.75 (0.42--1.32)                  0.31
  SM                                                                           8            12          74       16                  0.67 (0.30--1.49)                  0.33
  R                                                                            4             6          54       12                  0.46 (0.16--1.34)                  0.16
  HR                                                                           4             6          51       11                  0.49 (0.17--1.42)                  0.19
  **Treatment outcome of smear positive PTB treated with Category II**                                                                                                
  Cured/Treatment completed                                                   46            48          256      43                  1.21 (0.77--1.91)                  0.37
  Failure                                                                      4             4          56        9                  0.42 (0.11--1.18)                  0.09
  Loss to follow-up                                                           36            37          245      41                  0.90 (0.50--1.40)                  0.50
  Death                                                                        9             9          38        6                  1.60 (0.60--3.30)                  0.28
  Transferred                                                                  2             2           7        1                  1.59 (0.32--7.87)                  0.57

Odds ratio (95% CI) calculated with younger group as reference using chi-square test.

Sputum smear conversion rate at the end of IP in the elderly was 67% compared to 60% in younger; p = 0.20). Treatment outcomes did not differ between the two groups. ([Table 4](#pone-0088045-t004){ref-type="table"}). Drug susceptibility profile was available for 66 elderly and 452 younger patients. Susceptibility to first line anti-TB drugs did not differ between the groups. MDR-TB rates were lower among the elderly than in the younger group, but this was not statistically significant (6% vs. 11%, p = 0.19). ([Table 4](#pone-0088045-t004){ref-type="table"})

Discussion {#s4}
==========

TB is emerging as a significant health problem in the elderly [@pone.0088045-Sood1] and the control of TB in this group is essential for the overall success of TB control programmes. This study has documented that elderly TB patients are less likely to have smear positive disease and newly diagnosed elderly TB patients are more likely to default or die and report drug side effects, which is a matter of concern.

Sputum smear microscopy is the cornerstone of TB diagnosis. Similar to previous studies [@pone.0088045-Gaur1], [@pone.0088045-Pardeshi1], [@pone.0088045-Hauer1], we observed higher initial sputum smear negativity in the elderly. In support of this, a higher proportion of elderly patients received the Category III regimen compared to the younger (41% vs. 33%). In the RNTCP, diagnosis of smear negative TB is based on the persistence of respiratory symptoms and/or radiological abnormality despite a course of antibiotics. We do not have data on the proportion of patients in this study with radiological abnormality. Sputum culture is not routinely done in RNTCP and therefore we do not know the proportion of smear negative patients who were culture positive. Currently the TB Control programme classifies TB patients based on history of previous treatment as "New" or "previously treated" and offers only 2 types of regimen - Category I and II [@pone.0088045-Central2]. Nevertheless, the higher initial sputum smear negativity observed in the elderly may delay the diagnosis of TB. TB diagnostic algorithms should include other diagnostic tools apart from smear microscopy (eg. Xpert MTB/RIF) while evaluating the elderly for diagnosis of TB.

Smear conversion at the end of IP is an early predictor of treatment success [@pone.0088045-Zhao1]. Elderly new smear positive TB patients had lower smear conversion rates at the end of IP in this study (77% vs. 85%). This is similar to a previous study in which the sputum conversion rates at the end of the intensive phase were found to be significantly lower in the elderly in comparison to the younger TB patients (75.3% vs. 85.7%: p\<0.01) [@pone.0088045-Arora1]. There could be many reasons for this; including modification of treatment due to adverse effects of anti-TB drugs and associated illness [@pone.0088045-Arora1]. The possibility of malabsorption of anti-TB drugs in the elderly could also be considered since malabsorption of calcium, folate and Vitamin B~12~ has been reported in the elderly [@pone.0088045-Holt1].

The cure/treatment completion rate among new elderly TB patients was observed to be 71% in our study which is lower than the RNTCP objective of 85% cure rate [@pone.0088045-Central1]. This can be attributed to higher death (10%) and loss to follow-up rates (14%). A recent study from South India has documented a significantly higher risk (RR-1.4, 95% CI 1.2--1.6) of unfavourable treatment outcomes in older TB patients (16% compared with 11% for all others) with a stronger association among new TB patients [@pone.0088045-Ananthakrishnan1]. Death rate of 8% among new smear positive elderly TB patients has been documented in previous studies [@pone.0088045-Pardeshi1], [@pone.0088045-Rawat1]. The higher death rate among elderly TB patients has to be interpreted with caution since mortality increases with age. Higher mortality among TB patients aged 70 years or more has been reported [@pone.0088045-Ananthakrishnan1]. The cause of death in elderly TB patients can be difficult to determine, as TB may not be the only life-threatening disease and autopsies are rarely performed [@pone.0088045-Brinkmann1]. Nevertheless, in a study from Germany, TB as a post mortem diagnosis was more frequently established among elderly patients [@pone.0088045-Hauer1].

High loss to follow-up rates of 10.7% and 14.2% in the elderly were observed in previous studies [@pone.0088045-Arora1], [@pone.0088045-Pardeshi1] similar to our observation of 14%. The reasons cited for loss to follow-up in the elderly are poor memory, poor eyesight, low tolerance to therapy, mental confusion, associated depression, concomitant illness and logistic problems for regular visits to treatment centre [@pone.0088045-Arora1], [@pone.0088045-Sood1]. Loss to follow-up rate in the elderly could be reduced by ensuring good quality geriatric health services at the primary care level to address the various needs of the elderly population. Community geriatric health workers to provide home care may contribute to better TB management in the elderly.

We observed similar treatment outcomes among previously treated elderly and younger TB patients. Loss to follow-up rate was greater than 35% in these patients. Higher loss to follow-up rates for re-treatment patients have been documented in previous studies [@pone.0088045-Pardeshi1], [@pone.0088045-Santha1]. Adverse effects to anti-TB drugs either due to the bulk or toxicity was higher in elderly new TB patients (63% vs. 54%) in this study. A study from Korea documented higher drug-induced hepatitis, cutaneous toxicity, neurotoxicity, gastrointestinal disturbances, arthralgia, and flu-like syndrome in the elderly [@pone.0088045-LeeJ1]. Advancing age as an important predictor of hepatotoxicity due to H and R has been documented [@pone.0088045-Teale1], [@pone.0088045-Pande1]. Polypharmacy and age-related changes in responses to drugs and their elimination due to compromised hepatic and renal functions, contribute to drug adverse effects [@pone.0088045-Teale1]. Health care workers need to be aware of potential drug adverse effects for prompt intervention and appropriate management.

*M.tb* drug resistance rates were marginally lower, though not statistically significant, among elderly compared to younger patients, both among new and previously treated patients in this study. This is similar to a previous study which documented no significant differences in isoniazid-resistant TB and MDR TB between the two age groups [@pone.0088045-Kwon1]. Analysis of TB notification data from Germany documented markedly lower drug resistance rates in the elderly for any drug resistance (6.5% vs 13.9%; p\<0.001) and for MDR (0.6% vs. 3.1%; p\<0.001) [@pone.0088045-Hauer1]. The reason for this phenomenon could be that TB disease in the elderly is largely due to re-activation of infection acquired in the distant past when drug resistant rates were lower.

Pulmonary TB (PTB) was common in the elderly in our study. This is in conformity with previous studies which documented higher prevalence of PTB in the elderly [@pone.0088045-Arora1], [@pone.0088045-Pardeshi1]. Pulmonary TB is a disease with male preponderance. Higher proportion of males in the elderly observed in our study is similar to previous reports [@pone.0088045-Arora1], [@pone.0088045-Gaur1].

Smoking is a risk factor for the development of TB [@pone.0088045-Kolappan1]. A higher proportion of elderly males (46%vs 37%) were smokers in this study. A study from Amritsar among hospitalised TB patients showed no difference in smoking between the elderly and younger [@pone.0088045-Bhushan1] while a descriptive study in a cohort of 100 patients aged \>50 yrs from Himachal Pradesh documented 68% smoking [@pone.0088045-Arora2]. Smoking cessation interventions focusing on the elderly will be important to reduce the burden of complications due to TB.

Associated co-morbidities in the elderly are a challenge to both TB diagnosis and treatment. We observed similar prevalence of diabetes mellitus in both age groups. Prevalence of co-morbidities namely cardiovascular diseases, diabetes mellitus, and airway obstructive disease has been reported to be higher in older TB patients [@pone.0088045-Kwon1].

A systematic review documented old age as a risk factor for TB diagnostic delay, with factors such as poverty, social isolation, and specific health-seeking behaviour hampering the elderly in gaining timely access to medical care [@pone.0088045-Storla1]. We observed 63% illiteracy and a higher case detection rate by active case finding (through survey) in the elderly. In addition, the elderly were economically dependent, as 58% were unemployed which implies that family support was necessary for medical help. Organizing frequent TB screening camps and other methods for active case finding, mobile clinics and increasing awareness through mass media may enhance early TB case detection in the elderly.

The limitations of our study include the possibility of potential misclassification of some Category II as Category I patients due to concealed history of previous anti-TB treatment at the time of diagnosis. The information on some important risk factors, such as HIV infection that could influence treatment outcomes was not available. Diabetes was self reported and this probably contributed to its lower prevalence. In addition, we were unable to collect more details pertaining to toxicity of anti-TB treatment and investigate the cause of death. Data for radiological extent of disease and the exact duration of symptoms prior to diagnosis were not available.

In summary, our study has shown that elderly TB patients are less likely to have smear positive disease though the majority had pulmonary TB. Newly diagnosed elderly TB patients are more likely to be lost to follow-up or die and report drug side effects. Programme managers should develop appropriate interventions in consultation with geriatric specialists, for effective management of TB in this vulnerable population.
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